|
|
Post by centralcoastinvestor on Jan 4, 2019 10:10:00 GMT -5
On this mornings conference call, I heard Mike say that they would be presenting at the JP Morgan Conference. I have not seen any announcement on that. Has anyone else?
|
|
|
|
Post by #NoMoreNeedles on Jan 4, 2019 10:13:51 GMT -5
They will be meeting with parties without presenting.
|
|
|
|
Post by centralcoastinvestor on Jan 4, 2019 10:15:42 GMT -5
They will be meeting with parties without presenting. That makes sense. Thanks for clarifying. |
|
|
|
Post by #NoMoreNeedles on Jan 4, 2019 10:20:59 GMT -5
Mike briefly alluded to looking for a single global partner, in particular for launch in Europe.
|
|
|
|
Post by itellthefuture777 on Jan 4, 2019 13:19:32 GMT -5
Mike briefly alluded to looking for a single global partner, in particular for launch in Europe. Last time they partnered when sales were zero..it cost the partner $1 billion upfront..hmm.. |
|
|
|
Post by kc on Jan 4, 2019 13:35:03 GMT -5
Attending:
The purpose of going to JPM next week is to meet some new PHARMA partners and press the flesh. Not sure if Mike is presenting or just looking for new friends/partners/investors.
www.jpmorgan.com/global/healthcareconference
About
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
Presentation schedule evidently has not been posted yet.
But a good example of what goes on is on the Deloitte web site about their presentations and who from Deloitte will be there.
www2.deloitte.com/us/en/pages/mergers-and-acquisitions/events/jpm-healthcare-investor-conference.html
an example of some of the Deloitte folks there and their mission:
•Xander Alpherts, corporate finance partner, health care M&A leader, Deloitte Australia
•Richard Baderman, IT M&A transaction services partner, Deloitte United Kingdom
•Simon Brew, partner, Deloitte United Kingdom
•Carrie Chen, China financial advisory leader, corporate finance partner, Deloitte China
•Tal Chen, global technology alliances practice leader, partner, Deloitte Israel
•Jason Ding, managing director, corporate finance, life sciences and health care practice, Deloitte Canada
•Kazuhisa Go, corporate finance managing director, Deloitte Japan
•Stav Gregoriou, M&A transaction services director, Deloitte United Kingdom
•Rohan Hammett, consulting partner, Deloitte Australia
•John Haughey, lead partner for life sciences and health care for North West Europe, Deloitte United Kingdom
•Tim Hayden, M&A transaction services senior manager, Deloitte Canada
•Masafumi Ito, M&A transaction services partner, Deloitte Japan
•David Jones, European financial advisory leader, UK corporate finance partner, Deloitte United Kingdom
•Andy Khanna, corporatefinance partner, financial advisory life sciences leader, Deloitte India
•Andreas Korten, M&A transaction services partner, Deloitte Germany
•Dr. Sebastian Krolop, Monitor Deloitte partner, Deloitte US
•Susana Novo, Mexico life sciences and health care corporate finance lead partner, Deloitte Mexico
•Phil Pfrang, global life sciences and health care financial advisory managing partner, Deloitte US
•Jan Rattay, M&A transaction services partner,Deloitte United Kingdom
•Anthony Reid, director, Deloitte United Kingdom
•Anna Samanta, EMEA life sciences M&A lead partner, Deloitte Switzerland
•Amar Shah, corporate finance director, Deloitte United Kingdom
•Bill Stamatis, Canadian life sciences and health care lead partner, Deloitte Canada
•Colin Terry, United Kingdom/Swiss life sciences partner, Deloitte United Kingdom
•Michael van der Boom, M&A transaction services partner, Deloitte Switzerland
•Dr. Loke Wai Chiong, Southeast Asia health care sector leader partner, Deloitte Singapore
•Chris Woolley, United Kingdom life sciences lead partner, Deloitte United Kingdom
You have to be seen to get noticed, especially if you have some great positive things happening.
|
|
|
|
Post by kc on Jan 4, 2019 13:38:24 GMT -5
Another example is
westwicke.com/2018/11/5-things-to-look-for-at-the-2019-j-p-morgan-healthcare-conference/
5 Things to Look for at the 2019 J.P. Morgan Healthcare Conference
The J.P. Morgan Healthcare Conference provides an insightful beginning to the year. Beyond offering an opportunity to meet with analysts, investors, and other professionals in the healthcare industry, it illuminates trends that you’re likely to see throughout the upcoming year.
As you look forward to the 2019 event in January, start thinking about the information you can glean from the sessions you’ll attend, meetings you’ll facilitate, and announcements you’ll hear over the course of the conference.
Specifically, make sure you look out for these five things.
A glimpse into the 2019 M&A landscape
1. The J.P. Morgan Healthcare Conference is well-known as one of the premier places for companies to announce recent M&A deals. While 2017 saw a lull in announcements of M&A deals, the 2018 conference showed signs of renewed deal activity. 2018 U.S. tax cuts were predicted to spur M&A funding, especially in pharma and biotech — and that certainly proved true, as several large deals were announced at the very beginning of the year.
In 2019, be on the lookout for signs of the M&A landscape for the rest of the year. Are several big deals announced during the event, or is it on the quiet side? This can give you helpful insight into how the rest of the year will progress.
2. New industry trends to be aware of
You’ll likely notice a few key trends that flow throughout the conference and should guide your strategy in the coming year. In 2018, for example, the conference noted the importance of cybersecurity, engaging physicians, value-based payments, and pursuing multiple revenue streams.
Representatives from public companies who will be meeting with shareholders should keep an eye on these trends, as you’ll want to be prepared to discuss how you plan to take these trends into consideration over the coming year. Private companies with plans to go public in the coming year should also stay abreast of these trends to communicate their business value to potential investors.
3.Updates to the emerging trends of 2018
Each year, the J.P. Morgan Healthcare Conference highlights how the latest trends in technology — from drones to blockchain — are transforming healthcare and biotechnology.
During the 2018 conference, for example, there was much talk about the potential of artificial intelligence (AI) in healthcare. Ultimately, many experts and venture capitalists recommended that for now, AI is best suited for back-office and administrative functions, rather than clinical tasks. Now that companies have had another year to develop AI programs, will there be a renewed interest and potential in using AI for clinical tasks?
4.Insight into where investor money is going
The 2018 conference revealed that many investors are primarily interested in oncology startups that address topics like gene therapy and immunotherapy. MedCity News reported that these types of startups commanded the largest share of early-stage venture capital dollars in 2017, and predicted that that wouldn’t let up. During the 2019 conference, listen for indicators of what to expect in the year ahead — if investors will continue to pour dollars into oncology startups, or if the winds have changed and a new niche has stepped into the spotlight.
5.Unexpected but valuable connections
It’s easy to go into the J.P. Morgan Healthcare Conference with a schedule of wall-to-wall meetings. Between analysts and investors, you probably have a mile-long list of people you need to meet with. However, it’s just as important to be on the lookout for unconventional or unexpected connections — say, with people who are simply doing interesting things in the industry.
These people can give you more insight into the industry (including the trends and M&A landscape mentioned above), as well as strengthen your overall network.
By staying on the lookout for these five things, the 2019 J.P. Morgan Healthcare Conference will be an insightful way to start the year. But to get the most out of the event, it’s critical to begin planning now. For tips on getting your team ready, download our complimentary eBook, J.P. Morgan Healthcare Conference
westwicke.com/j-p-morgan-healthcare-conference-your-keys-to-success/
|
|
|
|
Post by kc on Jan 4, 2019 13:44:39 GMT -5
More from the San Fran Business Times
Get a room: How to work around biotech's big conference space crunch
www.bizjournals.com/sanfrancisco/news/2018/01/04/jpm18-meeting-space-biocom-biotech-showcase.html
By Ron Leuty
– Reporter, San Francisco Business Times
Jan 4, 2018, 5:36pm EST
Only in San Francisco — and only during the week of the biotech industry's biggest conference — can simply sitting down cost so much.
Welcome to the J.P. Morgan Healthcare Conference, where companies in a cash-flush industry are easy pickings as they try to complete critical connections from Sunday into Thursday with partners, venture capitalists or investment bankers.
The biotech industry, however, is getting savvier about finding space for one-on-one meetings between many of the roughly 20,000 people swarming to Union Square for the 36th annual conference and other events. But nailing down space depends on who you know — and even then, those friends must plan far ahead.
The California biotech industry trade group Biocom, for example, has converted a room at the Hotel Rex, about two blocks away from the Westin St. Francis, the host of the J.P. Morgan conference, that it is offering free to members in 30-minute increments for up to an hour a day.
"You used to be able to wait until October or November (to get a room), but now I have to reserve literally when I check out (the previous year)," said Biocom President and CEO Joe Panetta.
This is the second year Biocom has offered the space, which is fully booked from 8 a.m. Monday through 6 p.m. Wednesday.
"There's a premium on space. It's expensive," Panetta said.
Others are trying to find similar ways around the JPM space crunch.
Investment advisor TPP Healthcare, investment bank B. Riley FBR Inc. and financial communications firm Citigate Dewe Rogerson for this time this year reserved a conference room at the Parc 55 hotel that is available to their clients for free. It will have nearly 50 stations for one-on-one meetings.
"One of the biggest challenges during J.P. Morgan Healthcare week is securing meeting space for one-on-one meetings with investors and strategic partners," Vivian Chen, managing director at Citigate Dewe Rogerson, said in an email.
The space doesn't come cheap: Rooms during this year's 36th annual conference are going for about $1,000 a night. Smaller companies only a few years ago could book a room within walking distance of the conference for $300.
Those increased costs are consistent with a JPM premium charged since the biotech industry emerged from the Great Recession with science that has attracted billions of dollars in venture capital that have fed initial public offerings. Health care venture capital firms, for example, raised a record $9.1 billion last year, according to Silicon Valley Bank, a 26 percent increase from 2016.
Last year, the JW Marriott, a block away from the Westin St. Francis, charged $80 per hour — not including a 25 percent surcharge on all alcoholic beverages — for a table in its lobby lounge. Dining room tables at the hotel cost $60 with a per-person food and beverage minimum per hour up to two hours.
While some companies are able to plunk down the thousands of dollars it costs to convert a hotel room into a four-day meeting spot for executives, those prices add up for tight-pocketed small and midsize companies. While those ventures have raised tens of millions of dollars, research costs can siphon cash quickly.
As a result, many companies will continue to fight for a seat or two for meet-ups at restaurants, coffee shops and hotel lobbies in and around Union Square.
"We'll be going restaurant to restaurant, hotel lobby to hotel lobby," said Lisa Alderson, CEO of genetic testing and counseling startup Genome Medical Inc. "We looked into renting a conference room at a B-rate hotel a few blocks away, but it was $2,500 a day."
|
|
|
|
Post by itellthefuture777 on Jan 4, 2019 13:55:23 GMT -5
Mike briefly alluded to looking for a single global partner, in particular for launch in Europe. Last time they partnered when sales were zero..it cost the partner $1 billion upfront..hmm.. ..and..the stock price was about $11 to $12 pre reverse split or $55 to $60 a share in todays post split world..but that was..then..I imagine an EU partner could offer more and get less..as Mannkind is in a better fiscaL situation now..hmm..and we are only at $1.20? Scratching my head because with Sanofi that sold only 400 scripts..on their best day taking 33% to now where mannkind is over 700 and about to double for 2019 without giving up 33% to a partner..seems to me..no real reason to be less then 30% above what it was back then..to start then double at the end of the year..just for Afrezza..I am actually shocked this isn't currently at $50 moving to $100 to $200..yet it's a $1.20..superior insulin..better pricing..no needles..inhaled..superior glycemic controls..better insurance coverage..no RIMs..pedtiatric in clinicals..commercials comimg..and potentcially...more partners for Afrezza..for EU which..is a large market...I don't have any idea why this is at $1.20...but..since it is...  |
|
|
|
Post by harryx1 on Jan 4, 2019 14:31:40 GMT -5
|
|
|
|
Post by mnholdem on Jan 4, 2019 23:12:03 GMT -5
Last time they partnered when sales were zero..it cost the partner $1 billion upfront..hmm.. ..and..the stock price was about $11 to $12 pre reverse split or $55 to $60 a share in todays post split world..but that was..then..I imagine an EU partner could offer more and get less..as Mannkind is in a better fiscaL situation now..hmm..and we are only at $1.20? Scratching my head because with Sanofi that sold only 400 scripts..on their best day taking 33% to now where mannkind is over 700 and about to double for 2019 without giving up 33% to a partner..seems to me..no real reason to be less then 30% above what it was back then..to start then double at the end of the year..just for Afrezza..I am actually shocked this isn't currently at $50 moving to $100 to $200..yet it's a $1.20..superior insulin..better pricing..no needles..inhaled..superior glycemic controls..better insurance coverage..no RIMs..pedtiatric in clinicals..commercials comimg..and potentcially...more partners for Afrezza..for EU which..is a large market...I don't have any idea why this is at $1.20...but..since it is... I think your use of the word "upfront" is incorrect and misleading. Most of Sanofi's costs occurred with the Termination Agreement, a substantial portion of which was forgiveness of MannKind's 35% share of commercial expenses. Regardless, I would think that a truly global partner would provide a $100M+ upfront payment if Afrezza were performing better commercially in the U.S. |
|
|
|
Post by itellthefuture777 on Jan 4, 2019 23:42:39 GMT -5
..and..the stock price was about $11 to $12 pre reverse split or $55 to $60 a share in todays post split world..but that was..then..I imagine an EU partner could offer more and get less..as Mannkind is in a better fiscaL situation now..hmm..and we are only at $1.20? Scratching my head because with Sanofi that sold only 400 scripts..on their best day taking 33% to now where mannkind is over 700 and about to double for 2019 without giving up 33% to a partner..seems to me..no real reason to be less then 30% above what it was back then..to start then double at the end of the year..just for Afrezza..I am actually shocked this isn't currently at $50 moving to $100 to $200..yet it's a $1.20..superior insulin..better pricing..no needles..inhaled..superior glycemic controls..better insurance coverage..no RIMs..pedtiatric in clinicals..commercials comimg..and potentcially...more partners for Afrezza..for EU which..is a large market...I don't have any idea why this is at $1.20...but..since it is... I think your use of the word "upfront" is incorrect and misleading. Most of Sanofi's costs occurred with the Termination Agreement, a substantial portion of which was forgiveness of MannKind's 35% share of commercial expenses. Regardless, I would think that a truly global partner would provide a $100M+ upfront payment if Afrezza were performing better commercially in the U.S. Been awhile..it was $150 mil upfront.. |
|
|
|
Post by kc on Jan 4, 2019 23:49:58 GMT -5
Harry this is great stuff. I think they finally have figured out how to properly monetize technosphere. So many Pharma’s looking for their next big drug product. MannKind May hold the keys to a lot of new drugs. Or perhaps the paradigm shift in delivering in an old drug in new way. |
|
|
|
Post by lennymnkd on Jan 5, 2019 8:09:43 GMT -5
Also being able to renew patents with the platform is BIG !
|
|
|
|
Post by harryx1 on Jan 8, 2019 6:12:18 GMT -5
|
|
